Windtree Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a WINT research report →
Companywindtreetx.com
Windtree Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. The company's lead development programs include istaroxime, which is in Phase IIb clinical trial for the treatment of acute decompensated heart failure, as well as in Phase IIa clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase IIb clinical trial to treat respiratory distress syndrome in premature infants; Lyophilized KL4 surfactant, which is in Phase IIa clinical trial for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase IIb clinical trial for the treatment of genetically associated hypertension.
- CEO
- Jed A. Latkin
- IPO
- 1995
- Employees
- 14
- HQ
- Warrington, PA, US
Price Chart
Valuation
- Market Cap
- $579.79K
- P/E
- -0.00
- P/S
- 6.44
- P/B
- -0.00
- EV/EBITDA
- -0.31
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 12.22%
- Op Margin
- -37218.89%
- Net Margin
- -44447.78%
- ROE
- -1302.82%
- ROIC
- -454.89%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-5,487,000 · 72.96%
- EPS
- $-104.35 · 97.79%
- Op Income
- $-25,019,000
- FCF YoY
- -14.59%
Performance & Tape
- 52W High
- $1.86
- 52W Low
- $0.01
- 50D MA
- $0.02
- 200D MA
- $0.08
- Beta
- 1.76
- Avg Volume
- 365.59K
Get TickerSpark's AI analysis on WINT
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 3, 25 | KUCHARCHUK ANDREW ALBERT | other | 0 |
| Jan 8, 25 | Kelly Leanne | other | 0 |
| Oct 8, 24 | Fraser Craig | buy | 5,431 |
| Aug 13, 24 | PELLETIER SAUNDRA L | other | 0 |
| Aug 13, 24 | Latkin Jed | other | 0 |
| Jul 22, 24 | Simonson Steven | other | 2,674 |
| Jul 22, 24 | Simonson Steven | other | 13 |
| Jul 22, 24 | Fraser Craig | other | 4,011 |
| Jul 22, 24 | Fraser Craig | other | 19 |
| Sep 27, 23 | Fraser Craig | buy | 2,500 |
Our WINT Coverage
We haven't published any research on WINT yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate WINT Report →